Cndanting Wart Remover

Description

Salicylic acid is a colorless to white crystalline compound with a molecular weight of 138.12 g/mol. Its chemical formula is C7H6O3. Salicylic acid is commonly used in various pharmaceutical formulations and is recognized for its keratolytic and anti-inflammatory properties. The compound appears as a white powder or crystalline solid and is soluble in alcohol and ether, but only slightly soluble in water.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes, after which the area must be dried completely. A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is essential to allow the application to dry fully.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, as these may lead to adverse reactions or complications. Additionally, individuals with diabetes or poor blood circulation should not use this product, as it may pose significant risks to their health.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that is infected or reddened. It should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance immediately or contact the Poison Control Center at 1-800-222-1222.

Healthcare professionals should advise patients to discontinue use and consult a physician if discomfort persists. Monitoring for any adverse reactions is recommended to ensure patient safety.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and address any underlying issues that may arise during treatment.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Cndanting Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The product has not been evaluated for safety in pregnancy. Therefore, caution is advised when considering its use in pregnant patients, as the safety of salicylic acid during this period is not established. While specific potential risks to the fetus are not detailed, salicylic acid is generally recommended to be used with caution during pregnancy.

No specific dosage modifications for pregnant individuals are provided. It is essential for women of childbearing potential to consult a healthcare provider before using this product if they are pregnant or planning to become pregnant.

Lactation

There are no specific statements or information regarding nursing mothers or lactation in the provided drug insert for CNDANTING WART REMOVER (salicylic acid 17% wart remover liquid). Therefore, the effects on lactating mothers and breastfed infants are not established. Healthcare professionals should exercise caution when recommending this product to lactating mothers, as the absence of data does not rule out potential risks.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed.

Patients should be informed to avoid contact with their eyes. In the event that the product comes into contact with the eyes, they should flush the eyes with water for at least 15 minutes and seek medical attention if irritation persists.

It is important to emphasize that the product is non-edible. Patients should be instructed to keep the cap tightly closed and store the product at room temperature, away from heat sources.

Healthcare providers should also counsel patients to discontinue use and consult a doctor if discomfort continues after application.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The product is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Cndanting Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)